Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer
Recruiting
Observational Study
Renal Cancer
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To evaluate the utility of dual-energy spectral computed tomography (CT) scan in monitoring treatment in patients with metastatic clear cell carcinoma of the kidney. In particular, to analyze the use of spectral CT in patients who are candidates to receive first-line treatment based on combinations of immunotherapy and molecularly targeted drugs. In particular, the parameters derived from the use …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
* Age ≥ 18 years
* Patients with histological or cytological diagnosis of clear cell RCC
* Patients with metastatic disease documented by imaging or biopsy of the secondary site
* Patients who have not had previous treatment for RCC
* Patients with an indication for first-line me…
Contacts